AMH Blood Test Explained: What It Measures and Why It's Ordered

This page is for educational purposes only and is not medical advice; consult a licensed physician or the clinician who ordered the test about any individual laboratory value. Nothing below should be read as an interpretation of a personal result, and no reference ranges are offered here, because published reviews stress that cut-offs depend on the assay platform, the laboratory and the clinical question.

What anti-Müllerian hormone is and where it comes from

Anti-Müllerian hormone (AMH), historically called Müllerian-inhibiting substance, is a dimeric glycoprotein belonging to the transforming growth factor-β superfamily. In an endocrine review of ovarian reserve assessment, researchers described AMH in females as a product of the granulosa cells of preantral and small antral follicles, so that circulating concentrations broadly reflect the size of the pool of small growing follicles rather than the primordial pool directly (PMID 32770239).

Beyond acting as a marker, AMH has a described physiological role inside the ovary. A 2025 review of folliculogenesis reported that AMH participates in restraining the recruitment of primordial follicles and in modulating the responsiveness of growing follicles to follicle-stimulating hormone, positioning it as a regulator of the pace at which the follicle pool is used (PMID 40408029).

In males, the source is different. Reviews of Sertoli cell biology reported that AMH is secreted by Sertoli cells from fetal life onward, mediating regression of the Müllerian ducts during male sexual differentiation and remaining a marker of immature Sertoli cell activity afterwards (PMID 26859601). Work on prepubertal testicular evaluation described serum AMH as high during childhood and declining as intratesticular androgen exposure rises at puberty, which is why the same analyte carries different meaning at different ages (PMID 29982874).

What the AMH blood test actually measures

The test is a quantitative immunoassay performed on serum or plasma. Reviews of ovarian reserve testing reported that AMH measurement moved from manual enzyme-linked immunosorbent assays with differing antibody pairs and calibrators toward automated chemiluminescent platforms, and that this evolution improved reproducibility while leaving residual differences between methods (PMID 32770239). A clinical overview of AMH similarly described the analyte as measurable by several commercial assays whose results are not always numerically interchangeable, so that values are best compared within one platform (PMID 33041549).

A practical feature noted in the literature is timing. Researchers reported that AMH shows comparatively limited fluctuation across the menstrual cycle relative to gonadotrophins and oestradiol, which is one reason it has been studied as a cycle-independent marker of the growing follicle pool (PMID 32770239). A broader survey of endocrine biomarkers placed AMH among the analytes whose clinical value depends on assay standardisation and on matching the biomarker to a defined clinical question (PMID 24342177).

Why clinicians order an AMH test, as described in the literature

Assessment of ovarian reserve and assisted reproduction planning

The most frequently described indication is estimating ovarian reserve. The 2020 update on assessing ovarian function reported that AMH correlates with antral follicle count and with the number of oocytes retrieved after controlled ovarian stimulation, and that it is used alongside other markers when counselling about expected response (PMID 32770239). A companion clinical review described the same quantitative role, emphasising that AMH has been studied as a predictor of the quantity of the recruitable follicle cohort rather than of oocyte quality (PMID 33041549).

Polycystic ovary syndrome and polycystic ovarian morphology

A 2024 systematic review and meta-analysis evaluated AMH as a diagnostic biomarker and reported that serum AMH discriminated polycystic ovary syndrome and polycystic ovarian morphology from controls, while also reporting heterogeneity across studies and assays that complicated a single universal threshold (PMID 38944177). A review informing international PCOS guidelines reached a similar framing, reporting that elevated AMH reflects the increased number of small antral follicles characteristic of the syndrome and discussing whether AMH could substitute for ultrasound-based follicle counts (PMID 31160167). A 2021 mechanistic review examined AMH in the pathogenesis of PCOS as well as its diagnostic use, reporting associations between AMH and the hyperandrogenic and anovulatory features of the condition (PMID 34830389).

Research on the timing of menopause

A 2023 systematic review in Human Reproduction Update examined AMH for the diagnosis and prediction of menopause and reported that declining AMH is associated with approaching menopause at the population level, while noting that prediction of an individual woman's age at final menstrual period remained imprecise (PMID 36651193). The same review discussed how assay sensitivity at very low concentrations limits what can be concluded near the end of reproductive life (PMID 36651193).

Paediatric endocrinology and disorders of sex development

AMH is also ordered outside reproductive medicine. A review of clinical utility in paediatrics reported that AMH serves as a marker of Sertoli cell presence and function in boys and of ovarian tissue in girls, with applications in evaluating non-palpable gonads, suspected anorchia and ambiguous genitalia (PMID 34537849). A focused review of disorders of sex development reported that measurable AMH indicates functional testicular tissue in a child with undescended or impalpable testes, whereas undetectable values in that setting point away from it (PMID 33013698). Work on prepubertal testicular function described AMH, together with inhibin B, as a way to assess the seminiferous tubule compartment before puberty, when testosterone is uninformative (PMID 29982874).

What published studies associate with high AMH values

High AMH is most consistently discussed in the PCOS literature. The 2024 meta-analysis reported that women meeting PCOS criteria had higher serum AMH than controls and that AMH performed as a discriminating test for polycystic ovarian morphology, though the authors reported that optimal thresholds varied with assay and population (PMID 38944177). The guideline-informing review attributed that elevation to the enlarged cohort of small antral follicles and to granulosa-cell AMH production per follicle, and reported ongoing debate about whether AMH should be incorporated formally into diagnostic criteria (PMID 31160167).

A second context is a large recruitable follicle pool without pathology. The ovarian reserve update reported that higher AMH correlates with a greater number of oocytes retrieved during stimulation, and that this correlation also underlies interest in AMH as a way to anticipate exaggerated ovarian response (PMID 32770239). Mechanistic work reported that AMH itself influences follicle recruitment and FSH sensitivity, which complicates any simple reading of a high value as merely a counting exercise (PMID 40408029). In the PCOS pathogenesis review, researchers discussed AMH as potentially contributing to follicular arrest rather than only reflecting it (PMID 34830389).

What published studies associate with low AMH values

Low AMH has been studied mainly as a marker of a diminished pool of small growing follicles. The 2020 update reported that AMH declines with age and correlates with antral follicle count, and that low values are associated with fewer oocytes retrieved in stimulation cycles (PMID 32770239). The same literature reported that AMH is a quantitative rather than a qualitative marker, so low values were not established as a direct measure of oocyte competence (PMID 33041549).

In menopause research, the systematic review reported that low or undetectable AMH is associated with proximity to the final menstrual period, while cautioning that the predictive window for an individual remains wide (PMID 36651193). In paediatric male evaluation, reviewers reported that undetectable AMH in a 46,XY child with bilaterally impalpable gonads is consistent with absent testicular tissue, while low-for-age values may accompany Sertoli cell dysfunction (PMID 33013698, PMID 34537849).

Clinical contexts summarised

Assay and interpretation caveats: What Studies Report

• Assay dependence. Reviews reported that different commercial AMH assays have used different antibodies and calibrators, so numeric values and derived thresholds are not automatically transferable between laboratories (PMID 32770239, PMID 33041549).
• No single diagnostic cut-off. The 2024 meta-analysis reported substantial between-study heterogeneity in the AMH thresholds proposed for PCOS and polycystic ovarian morphology (PMID 38944177).
• Quantity, not quality. Clinical reviews reported that AMH has been validated chiefly as a marker of follicle number and expected stimulation response, not of embryo quality or of spontaneous conception in an individual (PMID 33041549, PMID 32770239).
• Age and life-stage dependence. Paediatric reviewers reported that AMH interpretation requires age- and sex-specific context, since values are physiologically high in prepubertal boys and fall at puberty (PMID 34537849, PMID 29982874).
• Low-end sensitivity. The menopause systematic review reported that assay performance at very low concentrations constrains conclusions in late reproductive life (PMID 36651193).
• Biomarker framing. A review of endocrine biomarkers reported that analytes such as AMH add value only when tied to a specific clinical question and a standardised method (PMID 24342177).

How the literature frames result interpretation

Across the sources summarised here, researchers presented AMH as one input among several — clinical history, ultrasound findings, gonadotrophins and, in paediatrics, karyotype and imaging — rather than as a standalone verdict (PMID 32770239, PMID 34537849). The PCOS literature in particular reported that AMH was evaluated as an adjunct to, or possible surrogate for, follicle counting rather than as an independent diagnosis (PMID 31160167). Any individual value, including one labelled high or low on a laboratory report, belongs to the ordering clinician to interpret within that fuller picture.

References

• Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function (The Journal of Clinical Endocrinology and Metabolism, 2020)
• AMH and Its Clinical Implications (Journal of Obstetrics and Gynaecology of India, 2020)
• Anti-müllerian hormone as a diagnostic biomarker for polycystic ovary syndrome and polycystic ovarian morphology: a systematic review and meta-analysis (Fertility and Sterility, 2024)
• Anti-Müllerian Hormone in PCOS: A Review Informing International Guidelines (Trends in Endocrinology and Metabolism, 2019)
• Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS (International Journal of Molecular Sciences, 2021)
• Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review (Human Reproduction Update, 2023)
• The Effect of AMH on Folliculogenesis (Reproductive Sciences, 2025)
• Clinical Utility of Anti-Mullerian Hormone in Pediatrics (The Journal of Clinical Endocrinology and Metabolism, 2022)
• What Does AMH Tell Us in Pediatric Disorders of Sex Development? (Frontiers in Endocrinology, 2020)
• Evaluation of testicular function in prepubertal children (Endocrine, 2018)
• The Sertoli cell: Novel clinical potentiality (Hormones, 2015)
• [Biomarkers in endocrinology] (Presse Médicale, 2014)